Product News: IDT launches rhAmpSeq™ CRISPR analysis system

Integrated DNA Technologies (IDT), a leading comprehensive genomics solutions provider, has launched its rhAmpSeq™ CRISPR Analysis System, which offers an end-to-end solution for characterizing and quantifying the full array of on- and off-target genome editing events in CRISPR research projects. 

The system harnesses the power of proprietary IDT rhAmpSeq technology, which enables highly accurate amplicon sequencing on Illumina next generation sequencing (NGS) platforms. The rhAmpSeq CRISPR Analysis System consists of design and synthesis of a custom rhAmpSeq CRISPR Panel, an efficient library kit, and access to data analysis through a user-friendly interface. This system offers a convenient workflow that enables sample-to-sequencer-to-results in less than a week. 

“This new system combines IDT’s leading Alt-R™ CRISPR genome editing reagents and innovative data analysis technology to provide researchers a complete solution,” said Trey Martin, IDT President. “As genome editing becomes more widespread, it is crucial to validate the editing and identify off-target effects. The rhAmpSeq CRISPR Analysis System addresses and uniquely enables this important researcher need.”

The system includes IDT’s rhAmpSeq CRISPR Analysis Tool, a cloud-based data analysis pipeline that produces publication-ready graphs and figures, helping researchers eliminate the need for bioinformatics resources or expertise. This comprehensive analysis tool is hosted by BlueBee, an Illumina company. BlueBee is a customizable, cloud-based data platform company that provides genomics analysis solutions. 

“Bioinformatics is a vital expertise that many labs do not have available. The rhAmpSeq CRISPR Analysis System helps to fill that gap and streamline workflows to get end results quickly and efficiently,” added Martin. “BlueBee is a valuable partner for IDT as their cloud-based genomics analysis solutions provide a secure, robust, scalable, and user-friendly platform for research.”  

“Illumina has a great history of partnership with IDT. We are pleased to extend this partnership and together provide researchers with an unparalleled ability to accelerate genome editing projects by translating raw sequencing data into human-readable information,” said Hans Cobben, Vice President of Software Development at Illumina.

Validation of specificity for CRISPR genome editing can be particularly beneficial for research projects that require detailed on- and off-target data analysis. The validation is also valuable for drug target discovery and for labs publishing in high impact journals. Off-target effects may have unwanted consequences; minimizing the risks associated with off-target genome editing is therefore essential. 

The rhAmpSeq CRISPR Analysis System is the latest addition to IDT’s expanding portfolio of Alt-R CRISPR genome editing products designed to meet the needs of CRISPR researchers. IDT’s product line offers a complete workflow – from design to analysis – to enable research projects through quality, simplicity, and cost efficiency. The Alt-R CRISPR portfolio is popular amongst many top academic researchers, as well as biotech and pharmaceutical companies.

Do you use Integrated DNA Technologies (IDT) products in your lab? Write a review today for your chance to win a $400 Amazon Gift Card>>